The flip side is good news: brand-name access is improving
This integrated approach not only promotes better patient adherence but also leads to lasting improvements in health outcomes and quality of life
Sources Eli Lilly TRIUMPH-4 Phase 3 trial results (December 2025) Eli Lilly TRIUMPH-1 Phase 3 topline results (May 21, 2026) Jastreboff AM, et al
However, the molecular targets of BH4-mediated direct antioxidant effect remain undefined, and specific research in the hyperglycemic and hypoxic pathological microenvironment of DR is lacking, with the heterogeneous role of BH4 in retinal cells yet to be further elucidated
Once target genes or cytokines are identified, transgenic mice overexpressing candidate gene constructs will be useful for testing whether a gene is sufficient to induce atrophy
Statements Author contributions YZ: Investigation, Writing original draft